Login to Your Account



Washington Roundup


Thursday, January 10, 2013
The FDA issued a draft guidance document to assist industry in developing new formulations of opioid drugs with abuse-deterrent properties. The document, titled "Guidance for Industry: Abuse-Deterrent Opioids – Evaluation and Labeling," contains the agency's current thinking about the studies that should be conducted to demonstrate that a given formulation has abuse-deterrent properties.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription